Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra.

Keidel SM, Hoyles RK, Wilkinson NM.

Rheumatology (Oxford). 2014 Mar;53(3):573-4. doi: 10.1093/rheumatology/ket211. Epub 2013 Aug 22. No abstract available.

PMID:
23970544
2.

Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome.

Shendi HM, Devlin LA, Edgar JD.

J Clin Rheumatol. 2014 Mar;20(2):103-5. doi: 10.1097/01.RHU.0000442576.41537.de.

PMID:
24561416
3.

Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra.

Botsios C, Sfriso P, Punzi L, Todesco S.

Scand J Rheumatol. 2007 May-Jun;36(3):236-7. No abstract available.

PMID:
17657682
4.

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.

Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN.

Arch Dermatol. 2006 Dec;142(12):1591-7.

PMID:
17178985
5.

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.

Kai AC, Flohr C, Grattan CE.

Clin Exp Dermatol. 2014 Jul;39(5):651-2. doi: 10.1111/ced.12320. Epub 2014 Apr 23. No abstract available.

PMID:
24758481
6.

Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up.

Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, Churchman SM, McDermott MF, Hawkins PN.

J Cutan Med Surg. 2008 Jan-Feb;12(1):8-16.

PMID:
18258152
7.

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.

Woerner A, von Scheven-Gête A, Cimaz R, Hofer M.

Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257. Epub 2015 Apr 4. Review.

PMID:
25843554
8.

Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.

Mohr M, Jacobi AM.

Scand J Rheumatol. 2011;40(5):400-1. doi: 10.3109/03009742.2011.599072. No abstract available.

PMID:
21961704
9.

The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients.

Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, Godmer P, Abasq C, Astudillo L, Belenotti P, Bessis D, Bigot A, Doutre MS, Ebbo M, Guichard I, Hachulla E, Héron E, Jeudy G, Jourde-Chiche N, Jullien D, Lavigne C, Machet L, Macher MA, Martel C, Melboucy-Belkhir S, Morice C, Petit A, Simorre B, Zenone T, Bouillet L, Bagot M, Frémeaux-Bacchi V, Guillevin L, Mouthon L, Dupin N, Aractingi S, Terrier B; French Vasculitis Study Group.

Arthritis Rheumatol. 2015 Feb;67(2):527-34. doi: 10.1002/art.38956.

10.

Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra).

Bodar EJ, Simon A, de Visser M, van der Meer JW.

Neth J Med. 2009 Oct;67(9):302-5.

11.

The rapidly evolving role of anakinra in dermatology: a double-edged sword.

Kapoor S.

J Am Acad Dermatol. 2008 Dec;59(6):1092-3. doi: 10.1016/j.jaad.2008.08.026. No abstract available.

PMID:
19022112
12.

Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study.

Krause K, Mahamed A, Weller K, Metz M, Zuberbier T, Maurer M.

J Allergy Clin Immunol. 2013 Sep;132(3):751-754.e5. doi: 10.1016/j.jaci.2013.04.008. Epub 2013 May 24. No abstract available.

PMID:
23711544
14.

A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.

Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K.

J Korean Med Sci. 2010 Sep;25(9):1364-7. doi: 10.3346/jkms.2010.25.9.1364. Epub 2010 Aug 12.

15.

Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.

Metyas SK, Hoffman HM.

J Rheumatol. 2006 Oct;33(10):2085-7. Epub 2006 Sep 15.

PMID:
16981288
16.

Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.

Cohen C, Mekinian A, Saidenberg-Kermanac'h N, Stirnemann J, Fenaux P, Gherardi R, Fain O.

Ann Rheum Dis. 2012 Apr;71(4):628-9. doi: 10.1136/annrheumdis-2011-200501. Epub 2011 Nov 25. No abstract available.

PMID:
22121135
17.

Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade.

Chu CQ.

J Rheumatol. 2010 Apr;37(4):881-2. doi: 10.3899/jrheum.091200. No abstract available.

18.

Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?

Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A.

Arthritis Rheum. 2009 Jan;60(1):264-8. doi: 10.1002/art.24174.

19.
20.

Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies.

Hedrich CM, Fiebig B, Sallmann S, Bruck N, Hahn G, Roesler J, Roesen-Wolff A, Heubner G, Gahr M.

Scand J Rheumatol. 2008 Sep-Oct;37(5):385-9. doi: 10.1080/03009740801978889.

PMID:
18609262

Supplemental Content

Support Center